TNXP [NASD]
Tonix Pharmaceuticals Holding Corp.
Index- P/E- EPS (ttm)-7.60 Insider Own0.07% Shs Outstand16.31M Perf Week3.65%
Market Cap32.44M Forward P/E- EPS next Y-6.72 Insider Trans- Shs Float- Perf Month-59.11%
Income-98.10M PEG- EPS next Q-1.60 Inst Own19.10% Short Float- Perf Quarter-64.50%
Sales- P/S- EPS this Y53.60% Inst Trans-10.13% Short Ratio0.80 Perf Half Y-87.26%
Book/sh12.75 P/B0.16 EPS next Y-5.00% ROA-45.20% Target Price54.40 Perf Year-94.45%
Cash/sh8.61 P/C0.23 EPS next 5Y- ROE-48.50% 52W Range1.91 - 45.44 Perf YTD-82.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-95.62% Beta1.58
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low4.19% ATR0.46
Employees73 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)27.22 Volatility17.34% 13.78%
OptionableNo Debt/Eq0.00 EPS Q/Q28.90% Profit Margin- Rel Volume1.33 Prev Close2.13
ShortableNo LT Debt/Eq0.00 EarningsMay 09 BMO Payout- Avg Volume1.84M Price1.99
Recom2.00 SMA20-46.49% SMA50-63.81% SMA200-83.79% Volume2,451,861 Change-6.57%
Apr-18-22Initiated Noble Capital Markets Outperform
Apr-18-19Upgrade ROTH Capital Neutral → Buy $4
Aug-18-17Upgrade ROTH Capital Neutral → Buy $6
Sep-07-16Downgrade ROTH Capital Buy → Neutral
Feb-17-16Reiterated Oppenheimer Outperform $18 → $10
Nov-04-15Initiated Cantor Fitzgerald Buy
Jun-12-15Initiated Oppenheimer Outperform $18
Feb-17-15Reiterated ROTH Capital Buy $10 → $12
Sep-29-14Reiterated ROTH Capital Buy $17 → $10
May-18-22 05:23PM  
07:00AM  
May-17-22 11:05AM  
May-16-22 06:40PM  
01:00PM  
09:30AM  
May-13-22 09:30AM  
May-09-22 04:50PM  
07:00AM  
Apr-28-22 07:00AM  
Apr-25-22 07:00AM  
Apr-20-22 07:00AM  
Apr-12-22 07:00AM  
Apr-11-22 09:47AM  
Apr-07-22 10:17AM  
07:00AM  
Apr-06-22 07:00AM  
Apr-05-22 07:00AM  
Mar-31-22 06:30AM  
Mar-22-22 07:00AM  
Mar-21-22 10:15AM  
07:00AM  
Mar-14-22 01:29PM  
07:00AM  
Mar-09-22 03:25PM  
07:00AM  
Mar-07-22 04:29PM  
10:22AM  
07:00AM  
Mar-04-22 03:54PM  
02:53PM  
11:03AM  
Mar-03-22 06:51PM  
07:00AM  
Feb-28-22 10:54AM  
09:30AM  
07:00AM  
Feb-25-22 09:15AM  
Feb-21-22 10:45AM  
Feb-18-22 04:50PM  
10:45AM  
Feb-14-22 10:45AM  
Feb-11-22 10:45AM  
Feb-07-22 10:15AM  
07:00AM  
Jan-12-22 04:46AM  
Jan-11-22 07:00AM  
Jan-05-22 07:00AM  
Jan-04-22 09:12AM  
07:00AM  
Dec-28-21 02:33PM  
10:13AM  
10:02AM  
Dec-23-21 02:33PM  
Dec-16-21 03:01PM  
01:29PM  
11:41AM  
09:57AM  
09:28AM  
Dec-15-21 05:06PM  
02:51PM  
07:00AM  
Dec-14-21 07:00AM  
Dec-13-21 10:52AM  
10:38AM  
09:20AM  
07:00AM  
Dec-10-21 09:00AM  
Nov-23-21 02:55PM  
07:00AM  
Nov-22-21 04:05PM  
Nov-16-21 02:36PM  
Nov-15-21 06:21PM  
07:00AM  
Nov-12-21 07:00AM  
Nov-10-21 03:49PM  
10:06AM  
Nov-09-21 11:42AM  
07:00AM  
Nov-08-21 04:05PM  
07:00AM  
Oct-21-21 07:00AM  
Oct-15-21 07:00AM  
Oct-14-21 09:15AM  
Oct-07-21 07:00AM  
Oct-04-21 11:45AM  
07:00AM  
Oct-01-21 12:30PM  
Sep-29-21 08:13AM  
Sep-27-21 07:00AM  
Sep-23-21 07:00AM  
Sep-22-21 07:00AM  
Sep-14-21 08:16AM  
Sep-13-21 08:00AM  
Sep-07-21 07:00AM  
Aug-24-21 02:14PM  
08:09AM  
07:00AM  
Aug-23-21 07:27PM  
Aug-19-21 09:54AM  
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LEDERMAN SETHChief Executive OfficerMar 25Buy0.24100,00024,500112,177Mar 28 08:00 AM
LEDERMAN SETHChief Executive OfficerSep 28Buy0.6112,0007,32012,177Sep 28 05:04 PM